MacroGenics, Inc. - Common Stock (NQ:MGNX)

3.580 -0.020 (-0.56%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MacroGenics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

MacroGenics (MGNX) Q1 2024 Earnings Call Transcript ↗

May 10, 2024

MGNX earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

MGNX Stock Earnings: Macrogenics Misses EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

MGNX stock results show that Macrogenics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 09, 2024

Via Benzinga

MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call

May 03, 2024

From MacroGenics, Inc.

Via GlobeNewswire

The Latest Analyst Ratings For Macrogenics ↗

April 04, 2024

Via Benzinga

MacroGenics Inc. (NASDAQ: MGNX) Leading the Way in Thursday Trading Based on Percentage Gain

April 04, 2024

Via Investor Brand Network

Macrogenics: Q4 Earnings Insights ↗

March 07, 2024

Via Benzinga

A Preview Of Macrogenics's Earnings ↗

March 06, 2024

Via Benzinga

Masters In Trading - Saturday, April 27 ↗

April 27, 2024

In this recap of the most recent trading session, I review my portfolio and share one of the trades taken this week.

Via Talk Markets

Look Out For These 6 Stocks As Analysts Predicts Major Gains, One Up To 82% ↗

April 05, 2024

Investment analysts have revised their price targets upwards for six major stocks this week, with one company expected to see an 82% surge. The revised targets include four U.S.-listed companies, with...

Via Benzinga

MacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer Candidate ↗

April 04, 2024

Update on MacroGenics Inc's Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo) for metastatic castration-resistant prostate cancer (mCRPC). Safety and preliminary efficacy data anticipated...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 04, 2024

Via Benzinga

Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session ↗

April 04, 2024

U.S. stock futures were higher this morning, with the Dow futures gaining by around 90 points on Thursday.

Via Benzinga

Topics Stocks

MacroGenics Inc. (NASDAQ: MGNX) is a Stock Spotlight on 3/5

March 05, 2024

Via Investor Brand Network

Analyst Expectations For Macrogenics's Future ↗

March 04, 2024

Via Benzinga

Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

April 04, 2024

Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3%...

Via Benzinga

MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

April 03, 2024

From MacroGenics, Inc.

Via GlobeNewswire

Decoding 4 Analyst Evaluations For Macrogenics ↗

February 14, 2024

Via Benzinga

MacroGenics Inc. (NASDAQ: MGNX) is a Stock Spotlight on 2/12

February 12, 2024

Via Investor Brand Network

MacroGenics Inc. (NASDAQ: MGNX) is a Stock Spotlight on 2/6

February 06, 2024

Via Investor Brand Network

MacroGenics (MGNX) Q4 2023 Earnings Call Transcript ↗

March 08, 2024

MGNX earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

MGNX Stock Earnings: Macrogenics Misses EPS for Q4 2023 ↗

March 07, 2024

MGNX stock results show that Macrogenics missed analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 07, 2024

Via Benzinga

AMD To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday ↗

March 04, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

MacroGenics to Participate in Upcoming Investor Conferences

March 01, 2024

From MacroGenics, Inc.

Via GlobeNewswire

MicroMarvel MacroGenics Confuses Wall Street ↗

February 05, 2024

100% technical buy signals. 15 new highs and up 66.53% last month. 280.00+ Weighted Alpha

Via Talk Markets

Earnings Scheduled For March 7, 2024 ↗

March 07, 2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.

Via Benzinga

MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call

February 27, 2024

From MacroGenics, Inc.

Via GlobeNewswire

Surgery Partners Posts Weak Sales, Joins Kosmos Energy, Moderna And Other Big Stocks Moving Lower On Monday ↗

February 26, 2024

U.S. stocks were slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Shares of Surgery Partners, Inc. (NASDAQ: SGRY) fell sharply during Monday’s session following weak...

Via Benzinga

Topics Stocks

MacroGenics to Participate in Upcoming Investor Conference

February 02, 2024

From MacroGenics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.